Interaction Checker

Interaksi Temozolomid

Temozolomid (Temodar) memiliki 32 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 9 mayor, 23 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (9)

  • DakarbazinMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Ekonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Flukonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Itrakonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Ketokonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Klotrimazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Mikonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Posakonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

  • Vorikonazolantijamur azolMayor

    TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (label Temozolomid, Kontraindikasi)

Interaksi moderat (23)

  • Azelastin dan flutikasonantihistaminModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

Periksa Temozolomid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.